ArticleDigestive diseases and sciences2017
Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes.
Article in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05184283 (Longitudinal Assessment of Muscle Health in Patients Undergoing Liver Transplantation), which is not on this map. Cited by 111 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Longitudinal Assessment of Muscle Health in Patients Undergoing Liver Transplantation (LT) for Hepatocellular Carcinoma (HCC)
Who cites it
111 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Pooled it
- Vitamin E for people with non-alcoholic fatty liver disease.The Cochrane database of systematic reviews · 2024Pooled it
- Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.The Cochrane database of systematic reviews · 2021Pooled it
- Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis.The Cochrane database of systematic reviews · 2021Pooled it
- Position statement on the diagnosis and management of non-alcoholic fatty liver disease.Saudi medical journal · 2019Pooled it
- Can Statin Treatment Reduce the Risk of Hepatocellular Carcinoma? A Systematic Review and Meta-Analysis.Technology in cancer research & treatmentPooled it
- Impact of Transjugular Intrahepatic Portosystemic Shunt on Waitlist and Post-transplant Outcomes in Liver Transplant Candidates.Digestive diseases and sciences · 2026Article
- Effects of Hydro-Ethanolic Extract ofHealth science reports · 2026Article
- Considerations in Liver Transplant Recipients Having Prior Roux-en-Y Gastric Bypass.Transplantation direct · 2026Article
- "Mycophenolate-Based Immunosuppression After Calcineurin-Inhibitor Withdrawal in Liver Transplant Recipients is Safe and Results in Long-Term Improvement in Renal Function".Clinical transplantation · 2026Article
- MMD-Net: a weakly supervised solution for quantification of nonalcoholic fatty liver biopsies.Quantitative imaging in medicine and surgery · 2026Article
- Liver transplantation in the era of obesity: A metabolic public health crisis meets a surgical frontier.Metabolism open · 2025Review
- Metabolic comorbidities and post-transplant outcomes in Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD): a cohort study from a Brazilian tertiary center.Archives of endocrinology and metabolism · 2025Article
- The newly proposed dietary index for gut microbiota and its association with the risk of nonalcoholic fatty liver disease: the mediating role of body mass index.Diabetology & metabolic syndrome · 2025Article
- Bempedoic acid suppresses diet-induced hepatic steatosis independently of ATP-citrate lyase.Cell metabolism · 2025Article
- Therapeutic effects of curcumin supplementation on liver enzymes of nonalcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.Food science & nutrition · 2025Review
- Efficacy of dietary polyphenol supplement in patients with non-alcoholic fatty liver disease: a network meta-analysis.Frontiers in nutrition · 2025Review
- Mitigating Cold Ischemic Injury: HTK, UW and IGL-2 Solution's Role in Enhancing Antioxidant Defence and Reducing Inflammation in Steatotic Livers.International journal of molecular sciences · 2024Article
- Sex-based Disparities in Liver Transplantation for Hepatocellular Carcinoma and the Impact of the Growing Burden of NASH.Transplantation direct · 2024Article
- Changing trends in the etiology of liver transplantation in Turkiye: A multicenter study.Hepatology forum · 2024Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsNonalcoholic steatohepatitis (NASH) is a rapidly growing etiology of end-stage liver disease in the US. Temporal trends and outcomes in NASH-related liver transplantation (LT) in the US were studied.
methodsA retrospective cohort study utilizing the United Network for Organ Sharing and Organ Procurement and Transplantation (UNOS/OPTN) 2003-2014 database was conducted to evaluate the frequency of NASH-related LT. Etiology-specific post-transplant survival was evaluated with Kaplan-Meier methods and multivariate Cox proportional hazards models.
resultsOverall, 63,061 adult patients underwent LT from 2003 to 2014, including 20,782 HCV (32.96%), 9470 ALD (15.02%), and 8262 NASH (13.11%). NASH surpassed ALD and became the second leading indication for LT beginning in 2008, accounting for 17.38% of LT in 2014. From 2003 to 2014, the number of LT secondary to NASH increased by 162%, whereas LT secondary to HCV increased by 33% and ALD increased by 55%. Due to resurgence in ALD, the growth in NASH and ALD was comparable from 2008 to 2014 (NASH +50.15% vs. ALD +41.87%). The post-transplant survival in NASH was significantly higher compared to HCV (5-year survival: NASH -77.81%, 95% CI 76.37-79.25 vs. HCV -72.15%, 95% CI 71.37-72.93, P < .001). In the multivariate Cox proportional hazards model, NASH demonstrated significantly higher post-transplant survival compared to HCV (HR 0.75; 95% CI 0.71-0.79, P < .001).
conclusionsCurrently, NASH is the most rapidly growing indication for LT in the US. Despite resurgence in ALD, NASH remains the second leading indication for LT.
Indexed as
Identifiers
28744836What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.